Dormitzer Philip R, Ulmer Jeffrey B, Rappuoli Rino
Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Ave., Cambridge, MA 02139, USA.
Trends Biotechnol. 2008 Dec;26(12):659-67. doi: 10.1016/j.tibtech.2008.08.002. Epub 2008 Oct 30.
Vaccine design is progressing from empiricism towards the increasingly rational presentation of the targets of protective immunity. Nevertheless, most current vaccine antigens are essentially the native macromolecules of pathogens. These molecules are adapted to evade, not induce, immunity. High resolution structures reveal the electrostatic surfaces recognized by neutralizing antibodies and the architectures underlying these surfaces, thereby identifying which substructures must be left intact and which can be changed to optimize biochemical and immunologic performance. Armed with detailed structural information, we can engineer optimized antigens that are more stable, homogeneous, and efficiently produced, making immunization more practical and affordable. Understanding the structural basis for immunogenicity and immunodominance will allow us to improve vaccine efficacy and broaden the range of vaccine-preventable diseases.
疫苗设计正从经验主义朝着更合理地呈现保护性免疫靶点的方向发展。然而,目前大多数疫苗抗原本质上是病原体的天然大分子。这些分子是为了逃避免疫而不是诱导免疫而进化的。高分辨率结构揭示了中和抗体识别的静电表面以及这些表面之下的结构,从而确定哪些亚结构必须保持完整,哪些可以改变以优化生化和免疫性能。有了详细的结构信息,我们就能设计出更稳定、均一且能高效生产的优化抗原,使免疫接种更具可行性且成本更低。了解免疫原性和免疫显性的结构基础将使我们能够提高疫苗效力,并扩大疫苗可预防疾病的范围。